Results 1 to 10 of about 87,373,768 (197)

Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders

Journal of Substance Abuse Treatment, 2020
Alan Budney, Lisa A Marsch, Stephen Metcalf   +2 more
exaly  

The case for a medication first approach to the treatment of opioid use disorder

American Journal of Drug and Alcohol Abuse, 2019
Rachel P Winograd, Ned Presnall
exaly  

A Scoping Review of Barriers and Facilitators to Implementation of Medications for Treatment of Opioid Use Disorder within the Criminal Justice System

International Journal of Drug Policy, 2020
Christine E Grella, Michael L Dennis, Christy K Scott   +2 more
exaly  

New Guidance Issued for Opioid Pain Medication

Ca-A Cancer Journal for Clinicians, 2004
exaly  

Opioid analgesics for nociceptive cancer pain: A comprehensive review

Ca-A Cancer Journal for Clinicians
Chris Hayes, Sujita W Narayan, Martin Underwood   +2 more
exaly  

Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults

Journal of Substance Use & Addiction Treatment
Stephanie Slat, Colin Macleod, Pooja Lagisetty   +2 more
exaly  

Telemedicine and increased retention in medications for opioid use disorder treatment [PDF]

Addiction Science & Clinical Practice
Background Buprenorphine is an effective treatment for Opioid Use Disorder (OUD), but many patients discontinue this medication within six-months of initiation and racial disparities in access and retention in buprenorphine treatment exist.
Allison J. Smith, Sara M. Witcraft, Suzanne Lane, Constance Guille   +3 more
doaj   +2 more sources

Statewide trends in access to medications for opioid use disorder (moud) among adolescents with opioid use disorders in Indiana [PDF]

Drug and Alcohol Dependence Reports
Purpose: Opioid use disorder (OUD) and related harms have risen among adolescents, yet access to medications for OUD (MOUD) remains limited, particularly among Medicaid-enrolled youth.
Sumedha Gupta, Katherine Schwartz, Lauren Arnold Bell, Nicole Siegal, Matthew C. Aalsma   +4 more
doaj   +2 more sources

The impact of methamphetamine use on medications for opioid use disorder (MOUD) treatment retention: a scoping review

Addiction Science & Clinical Practice, 2023
Background An emerging public health threat of methamphetamine/opioid co-use is occurring in North America, including increases in overdoses related to concomitant methamphetamine/opioid use.
Cayley Russell, Justine Law, Sameer Imtiaz, Jürgen Rehm, Bernard Le Foll, Farihah Ali   +5 more
doaj   +2 more sources

Leveraging pharmacy partnerships and Grant funding to improve access to medications for opioid use disorder [PDF]

Exploratory Research in Clinical and Social Pharmacy
Background: Increased availability and access to FDA-approved medications for opioid use disorder (MOUD) can improve efforts to address the ongoing opioid public health crisis.
John M. Vasko, Erin Shirley Orey, Carolanne Wartman, James K. Rowlett, Jefferson D. Parker, Donna M. Platt, Julie A. Schumacher   +6 more
doaj   +2 more sources